JDJoviane Daher

Joviane Daher

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Joviane Daher has a total of 36 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Glucose metabolism across COVID-19 and long COVID: a longitudinal study

    by Joviane Daher, Ziad Koberssy, Mireya Diaz, Sokratis N Zisis, Clifford J Rosen, Grace A McComsey

    Background: COVID-19 has been associated with new-onset diabetes. Prior studies are limited by lack of pre-infection data and preexisting cardiometabolic factors. Clarifying how COVID-19 and long COVID (LC) affect glucose metabolism is essential to guide prevention. We evaluated longitudinal changes in glycemic and cardiometabolic markers after SARS-CoV-2 infection in a prospective cohort with pre-infection baseline measurements. Methods: We included 821 uninfected adult participants from the RECOVER cohort who subsequently developed COVID-19, characterizing participants in their pre-COVID state. Data from up to 12 months post-infection were compared to pre-infection baseline. Participants with preexisting diabetes or pregnancy were excluded. The primary endpoint was change in HbA1c up to 12 months after infection. Analysis was stratified by LC status using the 2024 RECOVER Adult Long COVID Research Index (LCRI). Results: HbA1c remained stable from pre-infection to 12 months post-infection (5.39% vs 5.40%; P = .435). Non-HDL cholesterol and blood pressure decreased modestly, while cystatin C increased slightly; absolute changes were small. High-sensitivity C-reactive protein (hs-CRP), troponin, pro–brain natriuretic peptide (pro-BNP), body mass index, and waist circumference remained stable. The 10-year atherosclerotic cardiovascular disease (ASCVD) risk increased slightly (6.7% to 7.3%; P < .001). Trends were similar across LC groups. New-onset metabolic syndrome incidence was comparable across LC categories (18%-20%), although persistent metabolic syndrome was more frequent in participants with more severe LC. Conclusion: In this cohort with pre-infection baseline data, we found no significant changes in HbA1c or cardiometabolic biomarkers through 12 months after infection, although 10-year ASCVD risk slightly increased. These findings emphasize the importance of longitudinal assessment in differentiating transient physiological changes from persistent cardiometabolic disease after COVID-19.

  • Open Access

    Ultra-Processed Food Intake Is Not Associated with Systemic Inflammation in People with HIV

    by Ziad Koberssy, Aaron A. Fletcher, Joviane Daher, Jennifer E. Murphy, Jhony Baissary, Ornina Atieh, Kate Ailstock, Morgan Cummings, Nicholas T. Funderburg, Grace A. McComsey

    Background/Objectives: People with HIV (PWH) remain at high risk for cardiovascular and metabolic complications despite effective antiretroviral therapy (ART). Diet quality is an important modifiable factor that may influence these complications. Diets high in ultra-processed foods (UPF) have been linked to adverse metabolic and inflammatory profiles in the general population, but their impact on PWH remains poorly understood. The NOVA 4 classification categorizes foods by degree of processing, from unprocessed/minimally processed (NOVA 1) to UPF (NOVA 4). Methods: We conducted a cross-sectional study of adults with virologically suppressed HIV on stable ART. Assessments included dietary intake consisting of 24 h recalls analyzed with Nutrition Data System for Research software (NDSR) and classified into NOVA categories by a registered dietitian and the following characteristics: body composition (total and regional fat by DEXA and CT scan abdomen), cardiometabolic variables (glucose, HbA1C, HOMA-IR, lipids, blood pressure), and biomarkers of inflammation, immune activation, and gut integrity quantified by ELISA. Patients were stratified into NOVA 4 groups based on the median and quartile proportions of total energy intake from NOVA 4 foods. Associations between dietary NOVA and outcomes were analyzed using generalized additive models (GAMs) adjusted for age, sex, race, and CD4 count. Results: Among 222 PWH (mean age 45.4 ± 14.2 years; 31% female; 66% non-white; BMI 30.61 ± 7.91 kg/m2), median NOVA 4 intake was 45.6% of total energy intake. Participants with higher vs. lower NOVA 4 intake showed differences in diet quality, but in GAMs, higher NOVA 4 intake was not associated with higher levels of inflammatory, cardiometabolic, gut integrity, and body composition variables. Conclusions: In PWH, UPF consumption was high but not associated with markers of cardiometabolic health, systemic inflammation, or gut integrity. This may reflect the multifactorial nature of the heightened inflammation in PWH, potentially obscuring the effect of diet.

  • Comparison of Immune Activation and Gut Barrier Dysfunction between Long COVID and HIV infection

    by Ziad Koberssy, Joviane Daher, Jared C Durieux, Ornina Atieh, Jhony Baissary, Marc Abboud, Kate Ailstock, Morgan Cummings, Nicholas Funderburg, Grace A McComsey

    Human immunodeficiency virus (HIV) infection is characterized by persistent immune dysregulation and inflammation, with emerging evidence suggesting overlapping pathophysiological mechanisms with long coronavirus disease (COVID). Biomarkers of systemic inflammation and gut integrity may provide insight into shared and distinct pathways underlying these conditions. The status of the anti-inflammatory vitamin K may play a role in sustained inflammation in these conditions. This cross-sectional study enrolled participants belonging to 1 of 3 groups: individuals with long COVID without HIV (n = 108); participants with HIV (PWH) virologically suppressed with no previous COVID-19 infection (n = 256); and controls without long COVID or HIV (n = 193). Plasma samples were analyzed for inflammatory, gut integrity biomarkers, and dephosphorylated-uncarboxylated matrix Gla protein (dp-ucMGP) as an established marker of vitamin K status. Associations were assessed using multivariable linear and logistic regression models adjusted for demographic, metabolic, and lifestyle covariates. In total, 557 participants were included. Long COVID was independently associated with elevated oxidized low-density lipoprotein (β = .39 vs HIV, β = .54 vs controls; P < .001 for both). PWH had higher odds of worse vitamin K status (odds ratio, 1.5; 95% CI, 1.02–2.2; P = .04). Independent of long COVID or HIV status, worse vitamin K status was strongly associated with higher levels of inflammatory markers. Long COVID and HIV share chronic immune dysregulation features but demonstrate distinct inflammatory profiles. These findings highlight the importance of large longitudinal studies to delineate shared versus unique inflammatory pathways to guide potential long COVID therapeutic strategies. This graphical abstract is also available at Tidbit: https://tidbitapp.io/tidbits/omparison-of-immune-activation-and-gut-barrier-dysfunction-between-long-covid-and-hiv-infection?utm_campaign=tidbitlinkshare&utm_source=ITP

  • Effects of Semaglutide on Cognitive Function in People With HIV: A Randomized, Controlled Trial

    by Ornina Atieh, Joviane Daher, Marc Abboud, Qian Wu, Abdus Sattar, Jhony Baissary, Ziad Koberssy, Danielle Labbato, Allison Ross Eckard, Grace A McComsey

    Background: People with human immunodeficiency virus (HIV, PWH) are at higher risk for visceral adiposity, enhanced inflammation, and cognitive decline than controls who do not have HIV. We previously demonstrated that PWH with lipohypertrophy had a decrease in weight, visceral adipose tissue, and several inflammatory markers after receiving semaglutide, a glucagon-like peptide-1 receptor agonist. Our aim was to investigate the effect of semaglutide on cognitive function in PWH and the possible mediation of this effect by changes in adiposity or inflammation. Methods: In this randomized, double-blind, placebo-controlled phase 2b clinical trial, PWH on antiretroviral therapy were randomized 1:1 to receive 32 weeks of subcutaneous semaglutide or placebo. The primary outcome was the change in cognitive function at 32 weeks. Secondary measures included changes in body composition and inflammatory markers. Causal mediation analysis assessed semaglutide's direct and indirect effects on Cognivue scores through changes in adiposity and inflammation. Results: 108 participants were included (54 per arm); 65% were non-White, 40% were female, and median age was 53 years. Compared with placebo, PWH on semaglutide significantly increased visuospatial, naming/language, and delayed recall scores at 32 weeks (P = .01, .05, and .04, respectively). After adjusting for sex and absolute CD4 count, only visuospatial score remained statistically significant (P = .05). Semaglutide's total natural direct effect maintained a positive effect on the visuospatial score while accounting for potential changes in high-sensitivity C-reactive protein and soluble CD163 levels (P = .04). Conclusions: Semaglutide may have a beneficial impact on visuospatial cognitive function in PWH through its effect on inflammation. Clinical Trials Registration . NCT04019197.


  • Open Access

    Cognitive Function 1 Year After COVID Infection

    by Joviane Daher, Ziad Koberssy, Jared C Durieux, Ornina Atieh, Jhony Baissary, Marc Abboud, Grace A McComsey

    Background: While emerging evidence suggests a potential link between COVID-19 and cognitive impairment, there is a lack of prospective longitudinal research that objectively assesses cognitive outcomes after SARS-CoV-2 infection. This study aims to evaluate changes in cognitive function following COVID-19 in a group of individuals with baseline pre-infectious cognitive assessments. Methods: In this cohort study, cognitive function was objectively measured using the computerized Cognivue Clarity® device. All participants who had available Cognivue® testing were followed with a second Cognivue® assessment ∼1 year later. Based on whether they contracted COVID-19 during this period, participants were categorized into 2 groups according to COVID status. Results: We enrolled 110 participants with a median age of 45 years, 35% females and 46% white; 55 (50%) participants experienced a documented COVID-19 infection during the follow-up period (COVID + group), and the rest remained free of COVID infection (COVID- group). COVID- and COVID + groups were balanced for demographics and duration of follow-up. In the COVID + group, only memory scores changed during follow-up (+3.9; P = .03). The COVID- group showed improvements in the overall Cognivue® score (+2; P = .03), as well as in visuospatial (+1.9; P = .04), executive function (+2.2; P = .02), and naming language (+2.2; P = .01) scores. No statistically significant differences were observed in the overall cognitive score or its subdomains between the 2 groups. Conclusions: In a 45-year-old average population, no decrease in cognitive function was observed 1 year after COVID-19 infection.


  • Open Access

    Zinc Supplementation, Inflammation, and Gut Integrity Markers in HIV Infection: A Randomized Placebo-Controlled Trial

    by Jhony Baissary, Ziad Koberssy, Qian Wu, Abdus Sattar, Ornina Atieh, Joviane Daher, Kate Ailstock, Morgan Cummings, Danielle Labbato, Nicholas T. Funderburg, et al.

    Background: Low levels of zinc are prevalent in patients living with HIV and are associated with higher morbidity. Zinc has major immunomodulatory effects. This study aimed to assess the effect of zinc supplementation on inflammatory and gut integrity markers and on zinc levels among HIV patients with zinc deficiency. Methods: This was a double-blind randomized placebo-controlled trial assessing the efficacy and safety of zinc supplementation on inflammation and gut markers in people with HIV (PWH) ≥ 18 years old, on stable antiretroviral therapy (ART) with undetectable HIV-1 viral load, and with zinc levels of ≤0.75 mg/L. Participants were randomized 2:1 to zinc gluconate tablets at a dose of 90 mg of elemental zinc or a matching placebo daily for 24 weeks. At baseline and at week 24, we measured plasma levels of zinc and markers of inflammation and gut barrier integrity. Results: Among the 95 participants enrolled in this study, 74% were male, and 65% were non-white, with a median CD4 count of 722 cells/μL. The primary analysis showed an increase in zinc levels in the active group. A decrease in the monocyte activation marker soluble CD14 was observed in the treatment group at −56.31 ng/mL (−263.24; 134.19), compared to an increase in the placebo group of 101.71 ng/mL (−90.50; 243.20); p = 0.021. The stratified analysis showed that the group with the lowest zinc levels at baseline had the greatest improvements in soluble CD14 levels during zinc supplementation. No changes were seen in other inflammation markers or gut integrity markers. Conclusions: This is the most comprehensive study on the effect of zinc supplementation in PWH on inflammatory and gut integrity markers. Decreases were seen in the monocyte activation marker sCD14. In the contemporary HIV era with potent effective therapies, suppressed viremia, and high CD4 cells, zinc supplementation does not offer consistent benefits on inflammation.


  • Open Access

    The Effect of COVID-19 on Arterial Stiffness and Inflammation: A Longitudinal Prospective Study

    by Jhony Baissary, Ziad Koberssy, Jared C. Durieux, Ornina Atieh, Joviane Daher, Kate Ailstock, Danielle Labbato, Theresa Foster, Michael A. Rodgers, Alexander Merheb, et al.

    Data are limited for assessing the effect of COVID infection on endothelial function, pre- and post-pandemic. The objective of this study was to assess changes in pre-pandemic cardiovascular parameters after COVID-19 infection. This prospective cohort study used EndoPAT2000 Itamar Medical Ltd., Caesarea, Israel, to measure the augmentation index (AI; arterial elasticity) and reactive hyperemic index (RHI; endothelial function). Markers of endothelial function, inflammation, and gut integrity were collected at pre- and post-pandemic visits. COVID-negative and COVID-positive participants were matched on pre-pandemic covariates, and AI ≥ 5.0 was defined as having worse AI. Among the 156 participants, 50% had documented COVID-19 infection. Groups were balanced (p > 0.05) on pre-pandemic characteristics. Increases in oxLDL (p = 0.03) were observed in the COVID-positive group, and COVID infection had a negative effect on inflammatory markers (sVCAM-1, sTNF-RI, sTNF-RII, sCD14) and gut integrity (I-FABP, BDG) compared to COVID-negative participants (p < 0.05). There was a 16.7% (p = 0.02) increase in the proportion of COVID-positive participants with AI ≥ 5.0, without a significant change (p = 0.09) among the COVID-negative group. COVID-positive status, female sex, and higher IL-6 and sCD163 were associated (p < 0.05) with an increase in having worse AI. COVID infection is independently associated with arterial stiffness. For COVID survivors, female sex and higher markers of inflammation were associated with arterial stiffness.


  • Top Cited Papers
    Open Access

    Vitamins K2 and D3 Improve Long COVID, Fungal Translocation, and Inflammation: Randomized Controlled Trial

    by Ornina Atieh, Joviane Daher, Jared C. Durieux, Marc Abboud, Danielle Labbato, Jhony Baissary, Ziad Koberssy, Kate Ailstock, Morgan Cummings, Nicholas T. Funderburg, et al.

    Background: Long COVID (LC) is characterized by persistent symptoms at least 3 months after a SARS-COV-2 infection. LC has been associated with fungal translocation, gut dysfunction, and enhanced systemic inflammation. Currently, there is no approved treatment for this condition. The anti-inflammatory effect of vitamins K2 and D3 was shown to help attenuate the course of acute COVID-19 infection. Objective and hypothesis: This trial aims to investigate the effects of vitamins K2/D3 on LC symptoms, as well as gut and inflammatory markers, in people with established long COVID. Our hypothesis is that by attenuating systemic inflammation, vitamins K2/D3 will improve long COVID symptoms. Methods: This single-site randomized controlled study enrolled adults experiencing ≥2 moderate LC symptoms at least 3 months after a COVID-19 infection. The RECOVER Long COVID Research Index and number and type of LC symptoms were considered. Participants were randomized 2:1 to daily 240 µg K2 (pure MK-7 form) and 2000 UI vitamin D3 or standard of care (SOC) for 24 weeks. The endpoints were changes in symptomatology and in select inflammatory, metabolic, and gut biomarkers at 24 weeks. Results: We enrolled 151 participants (n = 98 received vit K2/D3 and 53 received SOC). The median age was 46 years; 71% were female and 29% were non-white. Baseline demographics were balanced between groups. At 24 weeks, the active treatment group only had a sharp increase in 25(OH) D, indicating good treatment adherence. In the vitamin K2/D3 arm, there was a 7.1% decrease in the proportion who had an LC Index ≥12 (vs. a 7.2% increase in the SOC group; p = 0.01). The average number of LC symptoms remained stable in the vitamin K2/D3 arm but increased in the SOC arm (p = 0.03). Additionally, reductions in oxidized LDL, inflammatory markers sTNF-RI and sCD163, and fungal translocation marker (1,3)-β-d-glucan were observed in the vitamin K2/D3 arm compared to the SOC arm (p < 0.01) over 24 weeks. Conclusions: Vitamins K2/D3 improved the RECOVER Long COVID Index, the number of LC symptoms, and several gut and inflammatory markers. Vitamins K2/D3 provide a promising safe intervention for people suffering from long COVID.


  • Open Access

    A Cross‐Sectional Look at HPV Vaccine Acceptance and Associated Factors Among Male University Students in Lebanon

    by Ziad Koberssy, Joey El Khoury, Rami Halabi, Joviane Daher, Nadine Saleh, Raghid El Khoury, Charbel El Hachem

    Background and aims: The human papillomavirus (HPV) is the leading sexually transmitted infection (STI) worldwide. Oncogenic HPV serotypes lead to various anogenital cancers in men. Societal changes in previously conservative regions like Lebanon have increased STI risks, particularly among university students. While several studies have focused on HPV prevalence in Lebanese females, data on males remain scarce. Men HPV vaccination is crucial for the prevention of HPV‐related cancers in both sexes. This study aims to assess vaccination prevalence among Lebanese male university students, identify influencing factors, and evaluate their HPV and its vaccine knowledge. Methods: This is a cross‐sectional analytical study surveying male students at Lebanese universities ranging from 17 to 30 years. Data were collected using closed‐ended questions distributed through an online platform. We compared vaccination rates with different variables using a bivariate analysis. The chi‐squared test was utilized for categorical variables, while Fisher’s exact test was employed for nonparametric evaluations of categorical data. For continuous variables, parametric and nonparametric analyses, the independent sample t ‐test, and the Mann–Whitney U test, respectively, are used. Throughout these investigations, statistical significance was set at a p ‐value ≤ 0.05 (95% confidence interval). Results: 324 individuals completed the study. HPV vaccination prevalence was 5.2% ( n = 17). In people not taking the HPV vaccine, limited knowledge of HPV (34.57%) and its vaccine (25.62%) as well as the lack of physician recommendation (31.17%) were the main barriers. Compared to their nonvaccinated peers (3.27 over 13), vaccinated participants (6 over 13) showed an increased HPV vaccination knowledge index ( p = 0.03). Conclusion: The study revealed diminished HPV vaccination rates among male university students in Lebanon, primarily attributed to inadequate knowledge and low physician recommendations. Targeted awareness campaigns and incorporating HPV vaccination into the national vaccination card are recommended to promote vaccination rates.